Search

Your search keyword '"Luppi Gabriele"' showing total 242 results
Start Over Author "Luppi Gabriele"
242 results on '"Luppi Gabriele"'

1. Leser-Trélat syndrome in patients affected by six multiple metachronous primitive cancers

Author

Giannetti Alberto, Losi Lorena, Luppi Gabriele, Ponti Giovanni, and Seidenari Stefania

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Leser-Trélat syndrome is characterized by the eruptive appearance of multiple seborrheic keratoses in association with underlying malignant disease. Usually, the sign of Leser-Trélat is associated with adenocarcinoma, most frequently of the colon, breast, or stomach, but also of the lung, kidney, liver, and pancreas. Herein, we present a case that we believe is the first report of the sign of Leser-Trélat in association with occult gastric adenocarcinoma and the anamnestic oncologic history of five other multiple primitive cancers. Epidermal growth factor receptor (EGFR) immunohistochemical expression analysis of multiple seborrheic keratoses revealed an intense membranous staining in the basal keratinocytes and in all the upper epidermal layers. Patients with the sign of Leser-Trélat should undergo a diagnostic screening programme for malignant disease along with patients with known Leser-Trélat syndrome who present with a recent acute and florid eruption of their seborrheic keratoses. We propose the importance of combining the molecular features of multiple seborrheic keratoses with EGFR immunohistochemistry analyses to determine the likelihood of Leser-Trélat syndrome and the consequent high risk of underlying multiple visceral malignancies.

Published
2010
Full Text
View/download PDF

2. Complete pathological response in a patient with multiple liver metastases from colon cancer treated with Folfox-6 chemotherapy plus bevacizumab: a case report

Author

Luppi Gabriele, Zironi Sandra, Bertolini Federica, Depenni Roberta, Ponti Giovanni, Malavasi Norma, and Conte Pier

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract The complete pathological response after primary chemotherapy could represent an important prognostic factor in patients affected by colorectal liver metastases. In recent studies, increasing complete pathological response seems to be correlated with longer overall survival periods and it is recognized as an important prognostic factor in patients treated with pre-operative chemotherapy. The correlation of radiological information on residual neoplastic disease after neoadjuvant treatment, obtained with CT and PET, has to be evaluated; in fact the complete disappearance of liver metastasis on radiological imaging does not always mean a complete disappearance of tumor tissue on histological examination; when it is documented with surgical procedures and confirmed by pathologist's examination, we can consider the complete pathological response. In recent years the addition of monoclonal antibodies to conventional chemotherapy may further increase the proportion of patients referred for surgery; bevacizumab before surgery has been shown to be feasible and safe, although concerns still exist regarding possible post-surgical and wound healing complications or bleeding. The limitation of the radiologic assessment of response as a surrogate for pathological response is even more relevant when antiangiogenic treatments are used. Excellent responses to bevacizumab-containing regimens do occur and referral to surgical oncology is a crucial step for documentation of complete pathological response.

Published
2009
Full Text
View/download PDF

3. Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study

Author

Marcheselli Luigi, Rashid Ivan, Cirilli Claudia, Valli Riccardo, Bertolini Federica, Rossi Giulio, Mucciarini Claudia, Luppi Gabriele, and Federico Massimo

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Although the diagnostic criteria and pathogenesis of gastrointestinal stromal tumors (GIST) have recently been elucidated, knowledge of the epidemiology of this malignancy is still limited. This study examined the incidence of GIST in the province of Modena, including pathologic features and clinical outcome. Methods Gastrointestinal mesenchymal tumors identified by the Modena Cancer Registry between 1991 and 2004 were analyzed with an immunohistochemical panel that included staining for CD-117 and PDGFRα. Size, mitotic rate, and other pathologic parameters were recorded. Each tumor was categorized into National Institutes of Health risk categories (very low, low, intermediate, and high risk). Results One hundred twenty-four cases were classified as GIST. The age-adjusted incidence rate was 6.6 per million. Seventy-five percent of patients were symptomatic; 34% had a previous or concomitant history of cancer. High-risk features were present in 47% of cases. Seventy-eight percent were submitted to radical surgery. After complete resection, the 5-year disease-free survival rates were 94%, 92%, 100%, and 40% for patients at very low, low, intermediate, and high risk, respectively. In multivariate analysis, high risk was the main predictor of recurrence. Conclusion This population-based study shows that the incidence of GIST in Northern Italy is comparable to that reported in other European countries. Survival was favorable in lower risk categories and in most of the resected cases. In our study, resected patients at very low, low, and intermediate risk had a similar outcome. Our data support the need to consider high-risk patients after complete surgical resection for treatment with the best available approach.

Published
2007
Full Text
View/download PDF

4. Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey

Author

Reni, Michele, Macchini, Marina, Orsi, Giulia, Peretti, Umberto, Valente, Mariamaddalena, Giommoni, Elisa, Antonuzzo, Lorenzo, Di Costanzo, Francesco, Bergamo, Francesca, Zagonel, Vittorina, Lonardi, Sara, Buggin, Federica, Milella, Michele, Palmerio, Silvia, Cavanna, Luigi, Di Nunzio, Camilla, Di Marco, Maria Cristina, Grassi, Elisa, Spada, Massimiliano, Messina, Marco, Cordio, Stefano, Avola, Francesco, Aprile, Giuseppe, Pagano, Salvatore, Simionato, Francesca, Cardellino, Giovanni Gerardo, Majer, Federica, Maiello, Evaristo, Latiano, Tiziana Pia, Chiarazzo, Cinzia, Artioli, Fabrizio, Razzini, Giorgia, Pasqualini, Antonella, Ghidini, Michele, Binda, Elisa, Lazzarelli, Silvia, Bozzarelli, Silvia, Sala, Simona, Luppi, Gabriele, Pettorelli, Elisa, Spallanzani, Andrea, Vicario, Giovanni, Salmaso, Flavia, Basso, Marco, Silvestris, Nicola, Del Curatolo, Sabina, Zustovich, Fable, Bongiovanni, Francesca, Longobardi, Ciro, Sandi, Ilenia, Fontanella, Caterina, Montelatici, Silvia, Giordano, Monica, Luchena, Giovanna, Gilardoni, Micol, Tamburini, Emiliano, Rudnas, Britt, Venturini, Barbara, Merelli, Barbara, Negrini, Giorgia, Vici, Elio Maria, Marabese, Alessandra, Garetto, Cristina, Curcio, Paola, Cinieri, Saverio, Cinefra, Margherita, Ferrara, Pasqualinda, Cantore, Maurizio, Morselli, Patrizia, Fumi, Guglielmo, Isidori, Agnese, Ciccarese, Giovanni, Paolo Frassineti, Giovanni Luca, Pagan, Flavia, Vaccaro, Vanja, Spoto, Chiara, Ferrara, Marianna, Garufi, Carlo, Caporale, Marta, Vasile, Enrico, Salani, Francesca, Barone, Elisa, Berardi, Rossana, Onofri, Azzurra, Ballatore, Zelmira, Lucarelli, Alessandra, Barucca, Alessandra, Pancotti, Amedeo, Scipioni, Teresa, Bencardino, Katia, Marrapese, Giovanna, Idotta, Laura, Petrelli, Fausto, Lonati, Veronica, Ceribelli, Anna, Giuli, Angelo, Zannori, Cristina, Bassanelli, Maria, Mambrini, Andrea, Ginocchi, Laura, Orlandi, Massimo, Celio, Luigi, Niger, Monica, Biamonte, Lavinia, Tamberi, Stefano, Piancastelli, Alessandra, Papiani, Giorgio, Valli, Irene, Allione, Paolo, Boe, Maria Giovanna, Scartozzi, Mario, Lai, Eleonora, Pireddu, Annagrazia, Ziranu, Pina, Demurtas, Laura, Puzzoni, Marco, Mariani, Stefano, Pretta, Andrea, Liscia, Nicole, Savastano, Clementina, Malaspina, Valentina, Tonini, Giuseppe, Grassani, Teresa, Barco, Barbara, Pierosandro, Tagliaferri, Ciliberto, Domenico, Ierardi, Antonella, Calandruccio, Natale Daniele, Minotti, Vincenzo, Matocci, Roberta, Torri, Valter, Porcu, Luca, Rulli, Erica, De Simone, Irene, Carlucci, Luciano, Rulli, Eliana, Poli, Davide, Tonto, Paola, Scellato, Francesca, Pinto, Carmine, Reni, M., Giommoni, E., Bergamo, F., Milella, M., Cavanna, L., Di Marco, M.C., Spada, M., Cordio, S., Aprile, G., Cardellino, G.G., Maiello, E., Bernardini, I., Ghidini, M., Bozzarelli, S., Macchini, M., Orsi, G., De Simone, I., Rulli, Er., Porcu, L., Torri, V., and Pinto, C.

Published
2023
Full Text
View/download PDF

5. Irinotecan-based chemotherapy in extrapulmonary neuroendocrine carcinomas: survival and safety data from a multicentric Italian experience

Author

Bardasi, Camilla, Spallanzani, Andrea, Benatti, Stefania, Spada, Francesca, Laffi, Alice, Antonuzzo, Lorenzo, Lavacchi, Daniele, Marconcini, Riccardo, Ferrari, Marco, Rimini, Margherita, Caputo, Francesco, Santini, Chiara, Cerma, Krisida, Casadei-Gardini, Andrea, Andrikou, Kalliopi, Salati, Massimiliano, Bertolini, Federica, Fontana, Annalisa, Dominici, Massimo, Luppi, Gabriele, and Gelsomino, Fabio

Published
2021
Full Text
View/download PDF

6. Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy

Author

O'Rourke, Colm J., Salati, Massimiliano, Rae, Colin, Carpino, Guido, Leslie, Holly, Pea, Antonio, Prete, Maria G., Bonetti, Luca R., Amato, Francesco, Montal, Robert, Upstill-Goddard, Rosie, Nixon, Colin, Sanchon-Sanchez, Paula, Kunderfranco, Paolo, Sia, Daniela, Gaudio, Eugenio, Overi, Diletta, Cascinu, Stefano, Hogdall, Dan, Pugh, Sian, Domingo, Enric, Primrose, John N., Bridgewater, John, Spallanzani, Andrea, Gelsomino, Fabio, Llovet, Josep M., Calvisi, Diego F., Boulter, Luke, Caputo, Francesco, Lleo, Ana, Jamieson, Nigel B., Luppi, Gabriele, Dominici, Massimo, Andersen, Jesper B., Braconi, Chiara, O'Rourke, Colm J., Salati, Massimiliano, Rae, Colin, Carpino, Guido, Leslie, Holly, Pea, Antonio, Prete, Maria G., Bonetti, Luca R., Amato, Francesco, Montal, Robert, Upstill-Goddard, Rosie, Nixon, Colin, Sanchon-Sanchez, Paula, Kunderfranco, Paolo, Sia, Daniela, Gaudio, Eugenio, Overi, Diletta, Cascinu, Stefano, Hogdall, Dan, Pugh, Sian, Domingo, Enric, Primrose, John N., Bridgewater, John, Spallanzani, Andrea, Gelsomino, Fabio, Llovet, Josep M., Calvisi, Diego F., Boulter, Luke, Caputo, Francesco, Lleo, Ana, Jamieson, Nigel B., Luppi, Gabriele, Dominici, Massimo, Andersen, Jesper B., and Braconi, Chiara

Abstract

Objective: Cytotoxic agents are the cornerstone of treatment for patients with advanced intrahepatic cholangiocarcinoma (iCCA), despite heterogeneous benefit. We hypothesised that the pretreatment molecular profiles of diagnostic biopsies can predict patient benefit from chemotherapy and define molecular bases of innate chemoresistance. Design: We identified a cohort of advanced iCCA patients with comparable baseline characteristics who diverged as extreme outliers on chemotherapy (survival <6 m in rapid progressors, RP; survival >23 m in long survivors, LS). Diagnostic biopsies were characterised by digital pathology, then subjected to whole-transcriptome profiling of bulk and geospatially macrodissected tissue regions. Spatial transcriptomics of tumour-infiltrating myeloid cells was performed using targeted digital spatial profiling (GeoMx). Transcriptome signatures were evaluated in multiple cohorts of resected cancers. Signatures were also characterised using in vitro cell lines, in vivo mouse models and single cell RNA-sequencing data. Results: Pretreatment transcriptome profiles differentiated patients who would become RPs or LSs on chemotherapy. Biologically, this signature originated from altered tumour-myeloid dynamics, implicating tumour-induced immune tolerogenicity with poor response to chemotherapy. The central role of the liver microenviroment was confrmed by the association of the RPLS transcriptome signature with clinical outcome in iCCA but not extrahepatic CCA, and in liver metastasis from colorectal cancer, but not in the matched primary bowel tumours. Conclusions: The RPLS signature could be a novel metric of chemotherapy outcome in iCCA. Further development and validation of this transcriptomic signature is warranted to develop precision chemotherapy strategies in these settings.

Published
2024

7. Non-Operative Management Versus Total Mesorectal Excision for Locally Advanced Rectal Cancer with Clinical Complete Response After Neoadjuvant Chemoradiotherapy: a GRADE Approach by the Rectal Cancer Guidelines Writing Group of the Italian Association of Medical Oncology (AIOM)

Author

Capelli, Giulia, De Simone, Irene, Spolverato, Gaya, Cinquini, Michela, Moschetti, Ivan, Lonardi, Sara, Masi, Gianluca, Carlomagno, Chiara, Corsi, Domenico, Luppi, Gabriele, Gambacorta, Maria Antonietta, Valvo, Francesca, Cannizzaro, Renato, Grillo, Federica, Barbaro, Brunella, Restivo, Angelo, Messina, Marco, Pastorino, Alessandro, Aschele, Carlo, and Pucciarelli, Salvatore

Published
2020
Full Text
View/download PDF

8. Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial

Author

Moussata, Driffa, Grangé, Jean-Didier, Ratziu, Vlad, Khemissa-Akouz, Faiza, Regnault, Hélène, Dauvois, Barbara, Zarski, Jean-Pierre, Ollivier-Hourmand, Isabelle, Manfredi, Sylvain, Debette-Gratien, Marilyne, Gangloff, Alice, Fontanges, Thierry, Baron, Aurore, Bouattour, Mohamed, Vincent, Julie, Sieghart, Wolfgang, Maieron, Andreas, Peeters, Marc, Delwaide, Jean, Lasser, Luc, Berg, Thomas, Schultheiß, Michael, Zipprich, Alexander, Trojan, Joerg, Ehmer, Ursula, Luppi, Gabriele, Luca, Giovanni, Tamberi, Stefano, Amoroso, Domenico, Alabiso, Oscar, Buonadonna, Angela, Toniutto, Pierluigi, Tamburini, Emiliano, Cubillo, Antonio, Muñoz, Andrés, Guillén, Carmen, Sánchez, Gloria, Manzano, Hermini, Navarro, Victor, Ales, Inmaculada, Massuti, Bartomeu, Dank, Magdolna, Bodoky, György, Kahan, Zsuzsanna, Horváth, Zsolt, Gabrail, Nashat, Ozer, Howard, Galanopoulos, Christos, Hauke, Ralph, Raj, Moses, Harputluoglu, Hakan, Sevinc, Alper, Goker, Erdem, Coker, Ahmet, Yalcin, Suayib, Ali, Muhammet, Ata, Ozlem, Tugba, Ilkay, El Kassas, Mohammed, Abdel, Amr, Wakid, Imam, Shamaa, Sameh, El Lahlouby, Nasr, Kohail, Hanaa, Makarem, Jawad, Chehade, Issam, Farhat, Fadi, López, Carlos, Marín, Miguel, Merle, Philippe, Blanc, Jean-Frederic, Phelip, Jean-Marc, Pelletier, Gilles, Bronowicki, Jean-Pierre, Touchefeu, Yann, Pageaux, Georges, Gerolami, René, Habersetzer, François, Nguyen-Khac, Eric, Casadei-Gardini, Andrea, Borbath, Ivan, Tran, Albert, Wege, Henning, Saad, Amr Shafik, Colombo, Massimo, Abergel, Armand, Richou, Carine, Waked, Imam, Yee, Nelson S, Molé, Audrey, Attali, Pierre, Le Boulicaut, Julie, and Vasseur, Bérangère

Published
2019
Full Text
View/download PDF

9. Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy

Author

O'Rourke, Colm J, primary, Salati, Massimiliano, additional, Rae, Colin, additional, Carpino, Guido, additional, Leslie, Holly, additional, Pea, Antonio, additional, Prete, Maria G, additional, Bonetti, Luca R, additional, Amato, Francesco, additional, Montal, Robert, additional, Upstill-Goddard, Rosie, additional, Nixon, Colin, additional, Sanchon-Sanchez, Paula, additional, Kunderfranco, Paolo, additional, Sia, Daniela, additional, Gaudio, Eugenio, additional, Overi, Diletta, additional, Cascinu, Stefano, additional, Hogdall, Dan, additional, Pugh, Sian, additional, Domingo, Enric, additional, Primrose, John N, additional, Bridgewater, John, additional, Spallanzani, Andrea, additional, Gelsomino, Fabio, additional, Llovet, Josep M, additional, Calvisi, Diego F, additional, Boulter, Luke, additional, Caputo, Francesco, additional, Lleo, Ana, additional, Jamieson, Nigel B, additional, Luppi, Gabriele, additional, Dominici, Massimo, additional, Andersen, Jesper B, additional, and Braconi, Chiara, additional

Published
2023
Full Text
View/download PDF

10. Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy

Author

O'Rourke, Colm J, Salati, Massimiliano, Rae, Colin, Carpino, Guido, Leslie, Holly, Pea, Antonio, Prete, Maria G, Bonetti, Luca R, Amato, Francesco, Montal, Robert, Upstill-Goddard, Rosie, Nixon, Colin, Sanchon-Sanchez, Paula, Kunderfranco, Paolo, Sia, Daniela, Gaudio, Eugenio, Overi, Diletta, Cascinu, Stefano, Hogdall, Dan, Pugh, Sian, Domingo, Enric, Primrose, John N, Bridgewater, John, Spallanzani, Andrea, Gelsomino, Fabio, Llovet, Josep M, Calvisi, Diego F, Boulter, Luke, Caputo, Francesco, Lleo, Ana, Jamieson, Nigel B, Luppi, Gabriele, Dominici, Massimo, Andersen, Jesper B, and Braconi, Chiara

Abstract

ObjectiveCytotoxic agents are the cornerstone of treatment for patients with advanced intrahepatic cholangiocarcinoma (iCCA), despite heterogeneous benefit. We hypothesised that the pretreatment molecular profiles of diagnostic biopsies can predict patient benefit from chemotherapy and define molecular bases of innate chemoresistance.DesignWe identified a cohort of advanced iCCA patients with comparable baseline characteristics who diverged as extreme outliers on chemotherapy (survival <6 m in rapid progressors, RP; survival >23 m in long survivors, LS). Diagnostic biopsies were characterised by digital pathology, then subjected to whole-transcriptome profiling of bulk and geospatially macrodissected tissue regions. Spatial transcriptomics of tumour-infiltrating myeloid cells was performed using targeted digital spatial profiling (GeoMx). Transcriptome signatures were evaluated in multiple cohorts of resected cancers. Signatures were also characterised using in vitro cell lines, in vivo mouse models and single cell RNA-sequencing data.ResultsPretreatment transcriptome profiles differentiated patients who would become RPs or LSs on chemotherapy. Biologically, this signature originated from altered tumour-myeloid dynamics, implicating tumour-induced immune tolerogenicity with poor response to chemotherapy. The central role of the liver microenviroment was confrmed by the association of the RPLS transcriptome signature with clinical outcome in iCCA but not extrahepatic CCA, and in liver metastasis from colorectal cancer, but not in the matched primary bowel tumours.ConclusionsThe RPLS signature could be a novel metric of chemotherapy outcome in iCCA. Further development and validation of this transcriptomic signature is warranted to develop precision chemotherapy strategies in these settings.

Published
2024
Full Text
View/download PDF

11. Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study

Author

Rizzo, Alessandro, primary, Salati, Massimiliano, additional, Frega, Giorgio, additional, Merz, Valeria, additional, Caputo, Francesco, additional, Di Federico, Alessandro, additional, Palloni, Andrea, additional, Carloni, Riccardo, additional, Ricci, Angela Dalia, additional, Gadaleta-Caldarola, Gennaro, additional, Messina, Carlo, additional, Spallanzani, Andrea, additional, Gelsomino, Fabio, additional, Benatti, Stefania, additional, Luppi, Gabriele, additional, Melisi, Davide, additional, Dominici, Massimo, additional, and Brandi, Giovanni, additional

Published
2022
Full Text
View/download PDF

12. Multicentre match-paired analysis of advanced biliary cancer long-term survivors: The BILONG study

Author

Caputo, Francesco, primary, Gelsomino, Fabio, additional, Spallanzani, Andrea, additional, Pettorelli, Elisa, additional, Benatti, Stefania, additional, Ghidini, Michele, additional, Grizzi, Giulia, additional, Ratti, Margherita, additional, Merz, Valeria, additional, Messina, Carlo, additional, Tonelli, Roberto, additional, Luppi, Gabriele, additional, Melisi, Davide, additional, Dominici, Massimo, additional, and Salati, Massimiliano, additional

Published
2022
Full Text
View/download PDF

13. CtDNA-guided rechallenge with anti-EGFR therapy in RASwt metastatic colorectal cancer: Evidence from clinical practice

Author

D’Onofrio, Raffaella, primary, Caputo, Francesco, additional, Prampolini, Francesco, additional, Spallanzani, Andrea, additional, Gelsomino, Fabio, additional, Bettelli, Stefania, additional, Manfredini, Samantha, additional, Reggiani Bonetti, Luca, additional, Carotenuto, Pietro, additional, Bocconi, Alessandro, additional, Dominici, Massimo, additional, Luppi, Gabriele, additional, and Salati, Massimiliano, additional

Published
2022
Full Text
View/download PDF

14. Statins increase pathological response in locally advanced rectal cancer treated with chemoradiation: a multicenter experience

Author

Caputo, Francesco, primary, Santini, Chiara, additional, Casadei-Gardini, Andrea, additional, Cerma, Krisida, additional, Bardasi, Camilla, additional, Garajovà, Ingrid, additional, Lattanzi, Elisabetta, additional, Passardi, Alessandro, additional, Rapposelli, Ilario Giovanni, additional, Spallanzani, Andrea, additional, Salati, Massimiliano, additional, Bonetti, Luca Reggiani, additional, Gelmini, Roberta, additional, Meduri, Bruno, additional, Piccoli, Micaela, additional, Pecchi, Annarita, additional, Benatti, Stefania, additional, Piacentini, Federico, additional, Dominici, Massimo, additional, Luppi, Gabriele, additional, and Gelsomino, Fabio, additional

Published
2022
Full Text
View/download PDF

16. The role of OFD1 and loss of primary cilia in cholangiocarcinoma: a novel promising therapeutic target

Author

Salati, Massimiliano, primary, Barbato, Anna, additional, Caputo, Francesco, additional, Spallanzani, Andrea, additional, Gelsomino, Fabio, additional, Ricco’, Betrice, additional, Luppi, Gabriele, additional, Ferrante, Luigi, additional, Biondi, Roberta, additional, Massaro, Francesco, additional, Iuliano, Antonella, additional, Gambardella, Gennaro, additional, Piscopo, Fabiola, additional, Pisapia, Pasquale, additional, Iaccarino, Antonino, additional, Salatiello, Maria, additional, Troncone, Giancarlo, additional, Reggiani-Bonetti, Luca, additional, Dominici, Massimo, additional, Franco, Brunella, additional, and Carotenuto, Pietro, additional

Published
2022
Full Text
View/download PDF

17. Nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Five-year follow-up from CheckMate 142.

Author

Overman, Michael J., primary, Lenz, Heinz-Josef, additional, Andre, Thierry, additional, Aglietta, Massimo, additional, Wong, Mark Ka, additional, Luppi, Gabriele, additional, Van Cutsem, Eric, additional, McDermott, Raymond S., additional, Hendlisz, Alain, additional, Cardin, Dana Backlund, additional, Morse, Michael, additional, Neyns, Bart, additional, Hill, Andrew Graham, additional, Limon, M. Luisa, additional, Garcia-Alfonso, Pilar, additional, Krishnamurthy, Anuradha, additional, Chen, Franklin, additional, Abdullaev, Sandzhar, additional, Soleymani, Samira, additional, and Lonardi, Sara, additional

Published
2022
Full Text
View/download PDF

19. Development and Multicentre Validation of the Modena Score to Predict Survival in Advanced Biliary Cancers Undergoing Second-Line Chemotherapy

Author

Salati, Massimiliano, primary, Marcheselli, Luigi, additional, Messina, Carlo, additional, Merz, Valeria, additional, Messina, Marco, additional, Carotenuto, Pietro, additional, Caputo, Francesco, additional, Gelsomino, Fabio, additional, Spallanzani, Andrea, additional, Reggiani Bonetti, Luca, additional, Caramaschi, Stefania, additional, Luppi, Gabriele, additional, Dominici, Massimo, additional, and Ghidini, Michele, additional

Published
2022
Full Text
View/download PDF

21. CtDNA-guided rechallenge with anti-EGFR therapy in RASwt metastatic colorectal cancer: Evidence from clinical practice

Author

D’Onofrio, Raffaella, Caputo, Francesco, Prampolini, Francesco, Spallanzani, Andrea, Gelsomino, Fabio, Bettelli, Stefania, Manfredini, Samantha, Reggiani Bonetti, Luca, Carotenuto, Pietro, Bocconi, Alessandro, Dominici, Massimo, Luppi, Gabriele, and Salati, Massimiliano

Abstract

Aim: To apply extended ctDNA-based RAS genotyping to clinical criteria for improving the selection of patients eligible for anti-EGFR-based rechallenge in a real-world setting.Methods: ctDNA testing was prospectively applied to RASwt mCRC progressed after a first-line anti-EGFR-containing regimen and at least one other line. The primary endpoint was the objective response rate.Results: Among ten enrolled patients, the anti-EGFR rechallenge resulted in an objective response rate and disease control rate of 70% and 90%. The median progression-free survival was 11.3 months and overall survival was not reached. Compared with a historical cohort retreated with anti-EGFR agents based on clinical criteria, the ctDNA-driven approach resulted in a higher chance of achieving an objective response and longer survival.Conclusions: Blood-based RASwt status may enrich metastatic colorectal cancer more likely to benefit from anti-EGFR-based rechallenge. RAS genotyping in ctDNA represents a feasible, fast, and cost-effective tool to be implemented in the clinic for advancing precision medicine.

Published
2023
Full Text
View/download PDF

23. Clinicopathologic correlates and prognostic relevance of the immune checkpoint CD73 (NT5E) in resected biliary cancers (BC).

Author

Salati, Massimiliano, primary, Caputo, Francesco, additional, Spallanzani, Andrea, additional, Gelsomino, Fabio, additional, Ricco', Beatrice, additional, Luppi, Gabriele, additional, Reggiani Bonetti, Luca, additional, Barbato, Anna, additional, Ferrante, Luigi, additional, Biondi, Roberta, additional, Iuliano, Antonella, additional, Gambardella, Gennaro, additional, Salatiello, Maria, additional, Iaccarino, Antonino, additional, Pisapia, Pasquale, additional, Troncone, Giancarlo, additional, Dominici, Massimo, additional, Franco, Brunella, additional, and Carotenuto, Pietro, additional

Published
2022
Full Text
View/download PDF

25. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study

Author

Lenz, Heinz-Josef, primary, Van Cutsem, Eric, additional, Luisa Limon, Maria, additional, Wong, Ka Yeung Mark, additional, Hendlisz, Alain, additional, Aglietta, Massimo, additional, García-Alfonso, Pilar, additional, Neyns, Bart, additional, Luppi, Gabriele, additional, Cardin, Dana B., additional, Dragovich, Tomislav, additional, Shah, Usman, additional, Abdullaev, Sandzhar, additional, Gricar, Joseph, additional, Ledeine, Jean-Marie, additional, Overman, Michael James, additional, and Lonardi, Sara, additional

Published
2022
Full Text
View/download PDF

26. Third-line chemotherapy in advanced biliary cancers (ABC): pattern of care, treatment outcome and prognostic factors from a multicenter study

Author

Salati, Massimiliano, primary, Rizzo, Alessandro, additional, Merz, Valeria, additional, Messina, Carlo, additional, Francesco, Caputo, additional, Gelsomino, Fabio, additional, Spallanzani, Andrea, additional, Ricci, Angela Dalia, additional, Palloni, Andrea, additional, Frega, Giorgio, additional, De Lorenzo, Stefania, additional, Carotenuto, Pietro, additional, Pettorelli, Elisa, additional, Benatti, Stefania, additional, Luppi, Gabriele, additional, Melisi, Davide, additional, Brandi, Giovanni, additional, and Dominici, Massimo, additional

Published
2021
Full Text
View/download PDF

28. Oral chemotherapy and patient perspective in solid tumors: a national survey by the Italian association of medical oncology

Author

Aurilio, Gaetano, Gori, Stefania, Nolè, Franco, Pruneri, Giancarlo, Coati, Francesca, Torri, Valter, Lunardi, Gianluigi, Atzori, Francesco, La Verde, Nicla, Banna, Giuseppe Luigi, Rossi, Antonio, Del Mastro, Lucia, Di Fabio, Francesca, Marcon, Ilaria, Gebbia, Vittorio, Loupakis, Fotios, Orlando, Laura, Ciuffreda, Libero, Amadio, Placido, Luppi, Gabriele, Redana, Stefania, Filippelli, Gianfranco, Gentile, Annalisa, and Collovà, Elena

Published
2016
Full Text
View/download PDF

33. Irinotecan Based Chemotherapy in Extrapulmonary Neuroendocrine Carcinomas: Survival and safety data from a Multicentric Italian Experience

Author

Bardasi, Camilla, primary, Spallanzani, Andrea, additional, Benatti, Stefania, additional, Spada, Francesca, additional, Laffi, Alice, additional, Lorenzo, Antonuzzo, additional, Lavacchi, Daniele, additional, Riccardo, Marconcini, additional, Marco, Ferrari, additional, Rimini, Margherita, additional, Caputo, Francesco, additional, Santini, Chiara, additional, Cerma, Krisida, additional, Casadei-Gardini, Andrea, additional, Andrikou, Kalliopi, additional, Salati, Massimiliano, additional, Bertolini, Federica, additional, Fontana, Annalisa, additional, Dominici, Massimo, additional, Luppi, Gabriele, additional, and Gelsomino, Fabio, additional

Published
2021
Full Text
View/download PDF

34. The Prognostic Role of Early Skeletal Muscle Mass Depletion in Multimodality Management of Patients with Advanced Gastric Cancer Treated with First Line Chemotherapy: A Pilot Experience from Modena Cancer Center

Author

Rimini, Margherita, primary, Pecchi, Annarita, additional, Prampolini, Francesco, additional, Bussei, Chiara, additional, Salati, Massimiliano, additional, Forni, Daniela, additional, Martelli, Francesca, additional, Valoriani, Filippo, additional, Canino, Fabio, additional, Bocconi, Alessandro, additional, Gelsomino, Fabio, additional, Reverberi, Linda, additional, Benatti, Stefania, additional, Piacentini, Federico, additional, Menozzi, Renata, additional, Dominici, Massimo, additional, Luppi, Gabriele, additional, and Spallanzani, Andrea, additional

Published
2021
Full Text
View/download PDF

37. Second-line chemotherapy (2L) in elderly patients with advanced biliary tract cancer (ABC): A multicenter real-world study.

Author

Rizzo, Alessandro, primary, Salati, Massimiliano, additional, Frega, Giorgio, additional, Merz, Valeria, additional, Caputo, Francesco, additional, Ricci, Angela Dalia, additional, Palloni, Andrea, additional, Messina, Carlo, additional, Spallanzani, Andrea, additional, Saccoccio, Gioconda, additional, Mollica, Veronica, additional, Gelsomino, Fabio, additional, Benatti, Stefania, additional, Luppi, Gabriele, additional, Melisi, Davide, additional, Dominici, Massimo, additional, and Brandi, Giovanni, additional

Published
2021
Full Text
View/download PDF

38. Subgroup analyses of patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line (1L) therapy:Two-year clinical update.

Author

Lenz, Heinz-Josef, primary, Lonardi, Sara, additional, Zagonel, Vittorina, additional, Van Cutsem, Eric, additional, Limon, M. Luisa, additional, Wong, Ka Yeung Mark, additional, Hendlisz, Alain, additional, Aglietta, Massimo, additional, Garcia-Alfonso, Pilar, additional, Neyns, Bart, additional, Luppi, Gabriele, additional, Cardin, Dana Backlund, additional, Dragovich, Tomislav, additional, Shah, Usman, additional, Yang, Jing, additional, Memaj, Arteid, additional, and Overman, Michael J., additional

Published
2021
Full Text
View/download PDF

39. The immune checkpoint CD73 (NT5E) in gastric adenocarcinoma (GAC): Biological characterization and clinical implications.

Author

Salati, Massimiliano, primary, Spallanzani, Andrea, additional, Gelsomino, Fabio, additional, Botticelli, Andrea, additional, Cerbelli, Bruna, additional, Riggi, Laura, additional, Bocconi, Alessandro, additional, D'Onofrio, Raffaella, additional, Benatti, Stefania, additional, Luppi, Gabriele, additional, and Dominici, Massimo, additional

Published
2021
Full Text
View/download PDF

48. Activity and safety of temozolomide in advanced adrenocortical carcinoma patients

Author

Cosentini, Deborah, primary, Badalamenti, Giuseppe, additional, Grisanti, Salvatore, additional, Basile, Vittoria, additional, Rapa, Ida, additional, Cerri, Sara, additional, Spallanzani, Andrea, additional, Perotti, Paola, additional, Musso, Emanuela, additional, Laganà, Marta, additional, Ferrari, Vittorio D, additional, Luppi, Gabriele, additional, Dalla Volta, Alberto, additional, Incorvaia, Lorena, additional, Sigala, Sandra, additional, Russo, Antonio, additional, Volante, Marco, additional, Terzolo, Massimo, additional, and Berruti, Alfredo, additional

Published
2019
Full Text
View/download PDF

49. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial

Author

Reni, Michele, Cordio, Stefano, Milandri, Carlo, Passoni, Paolo, Bonetto, Elisa, Oliani, Cristina, Luppi, Gabriele, Nicoletti, Roberto, Galli, Laura, Bordonaro, Roberto, Passardi, Alessandro, Zerbi, Alessandro, Balzano, Gianpaolo, Aldrighetti, Luca, Staudacher, Carlo, Villa, Eugenio, and Di Carlo, Valerio

Published
2005
Full Text
View/download PDF

50. Third-line chemotherapy in advanced biliary cancers (ABC): pattern of care, treatment outcome and prognostic factors from a multicenter study.

Author

Salati, Massimiliano, Rizzo, Alessandro, Merz, Valeria, Messina, Carlo, Francesco, Caputo, Gelsomino, Fabio, Spallanzani, Andrea, Ricci, Angela Dalia, Palloni, Andrea, Frega, Giorgio, De Lorenzo, Stefania, Carotenuto, Pietro, Pettorelli, Elisa, Benatti, Stefania, Luppi, Gabriele, Melisi, Davide, Brandi, Giovanni, and Dominici, Massimo

Subjects
PROGNOSIS, TREATMENT effectiveness, PROPORTIONAL hazards models, GALLBLADDER cancer, KAPLAN-Meier estimator, MONOCYTE lymphocyte ratio
Abstract

Here, we aim at describing the pattern of care, survival outcome and prognostic factors of ABC patients (pts) receiving third-line chemotherapy. Institutional registries across three academic medical centers were retrospectively reviewed. Kaplan–Meier estimators were used to calculate survival, the log-rank test to make comparisons, and the Cox proportional hazard models to assess the progostic impact of variables. Among 101 pts included in the analysis. 68 (67.3%), 19 (18.8%) and 14 (13.8%) had intrahepatic and extrahepatic cholangiocarcinoma and gallbladder cancer, respectively. Atotal of 63 (62.3%) pts received monochemotherapy, while 38 (37.6%) were treated with adoublet. The median OS and PFS were 5 and 3 months, respectively. Disease control rate was achieved in 23 (22.7%) pts, with 2 (2%) partial responses. Grade 3–4 treatment-related adverse events were reported in 22 (21.7%) pts. At multivariate analysis, ECOG PS (p < 0.001), tumor burden (p = 0.01) and lymphocyte-to-monocyte ratio (p =0.02) were independent predictors of survival. Third-line chemotherapy displayed limited activity in this real-world cohort, although prognostic factors have been identified that may assist in treatment decision. The results of this multicenter experience, highlight the need for more effective therapies and provide a benchmark for future trials in this setting. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results